Manus Neurodynamica Announces Agreement Has Been Signed with Medispa to Integrate NeuroMotor Pen Into Prevention Suite

Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has signed an agreement with Medispa, an Italian provider of wellness management systems and services, to integrate the NeuroMotor PenTM (‘NMP’) with Medispa’s Prevention Suite, an integrated platform of health services aimed at monitoring the health and well-being status of patients.

The agreement will focus on three target markets: pharmacy retail screening, patient screening in trials for pharmaceutical companies and large corporations that optimize prevention screening for their employees.

Medispa has developed the Prevention Suite platform, which is used by more than 10,000 pharmacies in Italy, Spain and Portugal, offering a wide range of health assessment devices and tests, connected by a single hub place in the pharmacy, to patients focused on their health and wellbeing. The platform does not currently offer any movement disorder screening.

The collaboration will allow the NMP to be integrated into Medispa’s Prevention Suite, allowing a much larger patient population to have access to the quick low-cost screening test, with an accuracy that is normally only available at specialist clinics. The technical integration of NMP with the Medispa Prevention Suite has been completed and is now fully setup for the patient pathway. Test reports from the NMP have been co-designed and optimized by Medispa to provide the right level of detail in an easily understandable way to both patient and clinician. The collaboration has also successfully completed a pilot screening scheme in a flagship pharmacy in Erba.

Medispa will be showcasing its partnership with Manus from today at the Cosmofarma Exhibition taking place in Bologna, Italy, held from 5-8 May. The exhibition is the world’s leading European event for Health Care, Beauty Care and all pharmacy-related services bringing together experts in the field.

Dr Rutger Zietsma, CEO of Manus, commented: “We are delighted to partner with Medispa as a key player in the healthcare system, to make the NMP more widely available via Medispa’s established Prevention Suite platform. This agreement will provide Manus with the opportunity to target a larger market including drugstores, primary-care physicians, community and hospital-based neurologists/movement disorder clinics and payers.

“Waiting lists and the availability of primary care clinicians is sometimes poor in the current healthcare setting and, with an aging population, there is a large and growing unmet need for early access to an affordable assessment to improve the patient pathway in Parkinson’s Disease and provide reassurance to individuals with benign movement symptoms. Parkinson’s symptoms overlap with other disease symptoms, and the clinical challenge when diagnosing patients is differentiating between Parkinson’s and other movement disorders. Screening facilities at or alongside primary care are much needed to improve the pathway and reduce costs, and this Medispa agreement is a great first step to achieving this.”

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kleiner Device Labs will attend the meeting and looks forward to demonstrating the new KG®2 Surge® flow-thru interbody system to surgeons
“Medtronic is continuing our efforts to stop Axonics from profiting off of their unauthorized use of our innovations and intellectual property," said Mira Sahney, president of the pelvic health business in the neuroscience portfolio at Medtronic. "The pattern is clear: Axonics uses Medtronic technologies to improperly compete in the market. It is time for Axonics to be held accountable for these unlawful acts."
The addition of Frank J Veith, MD to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies. His vast experience and achievements will provide critical insights and direction as ViTAA continues to pursue its goal of revolutionizing patient care through cutting-edge solutions.
Ultralife Corporation will join forces with cart manufacturer Karta to launch a complete medical cart and power solution on booth 1237 (Hall A) at HIMSS, from March 12-14, 2024 at the Orange County Convention Center in Orlando, Florida.
“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy